Skip Navigation
Skip to contents

J Pathol Transl Med : Journal of Pathology and Translational Medicine

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
3 "Soyeon An"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Article
Loss of Progesterone Receptor Expression Is an Early Tumorigenesis Event Associated with Tumor Progression and Shorter Survival in Pancreatic Neuroendocrine Tumor Patients
Sung Joo Kim, Soyeon An, Jae Hoon Lee, Joo Young Kim, Ki-Byung Song, Dae Wook Hwang, Song Cheol Kim, Eunsil Yu, Seung-Mo Hong
J Pathol Transl Med. 2017;51(4):388-395.   Published online June 8, 2017
DOI: https://doi.org/10.4132/jptm.2017.03.19
  • 6,473 View
  • 133 Download
  • 14 Web of Science
  • 13 Crossref
AbstractAbstract PDF
Background
Pancreatic neuroendocrine tumors (PanNETs) are the second most common pancreatic neoplasms and there is no well-elucidated biomarker to stratify their detection and prognosis. Previous studies have reported that progesterone receptor (PR) expression status was associated with poorer survival in PanNET patients.
Methods
To validate previous studies, PR protein expression was assessed in 21 neuroendocrine microadenomas and 277 PanNETs and compared with clinicopathologic factors including patient survival.
Results
PR expression was gradually decreased from normal islets (49/49 cases, 100%) to neuroendocrine microadenoma (14/21, 66.6%) to PanNETs (60/277, 21.3%; p < .001). PanNETs with loss of PR expression were associated with increased tumor size (p < .001), World Health Organization grade (p = .001), pT classification (p < .001), perineural invasion (p = .028), lymph node metastasis (p = .004), activation of alternative lengthening of telomeres (p = .005), other peptide hormonal expression (p < .001) and ATRX/DAXX expression (p = .015). PanNET patients with loss of PR expression (5-year survival rate, 64.1%) had significantly poorer recurrence-free survival outcomes than those with intact PR expression (90%) by univariate (p = .012) but not multivariate analyses. Similarly, PanNET patients with PR expression loss (5-year survival rate, 76%) had significantly poorer overall survival by univariate (p = .015) but not multivariate analyses.
Conclusions
Loss of PR expression was noted in neuroendocrine microadenomas and was observed in the majority of PanNETs. This was associated with increased grade, tumor size, and advanced pT and pN classification; and was correlated with decreased patient survival time by univariate but not multivariate analyses. Loss of PR expression can provide additional information on shorter disease-free survival in PanNET patients.

Citations

Citations to this article as recorded by  
  • Venous invasion and lymphatic invasion are correlated with the postoperative prognosis of pancreatic neuroendocrine neoplasm
    Sho Kiritani, Junichi Arita, Yuichiro Mihara, Rihito Nagata, Akihiko Ichida, Yoshikuni Kawaguchi, Takeaki Ishizawa, Nobuhisa Akamatsu, Junichi Kaneko, Kiyoshi Hasegawa
    Surgery.2023; 173(2): 365.     CrossRef
  • Combined Infiltrative Macroscopic Growth Pattern and Infiltrative Microscopic Tumor Border Status Is a Novel Surrogate Marker of Poor Prognosis in Patients With Pancreatic Neuroendocrine Tumor
    Bokyung Ahn, Joo Young Kim, Seung-Mo Hong
    Archives of Pathology & Laboratory Medicine.2023; 147(1): 100.     CrossRef
  • HORMONET: a phase II trial of tamoxifen for estrogen/progesterone receptor-positive neuroendocrine tumors
    Milton J. Barros, Jonathan Strosberg, Taymeyah Al-Toubah, Victor Hugo F. de Jesus, Lais Durant, Celso A. Mello, Tiago C. Felismino, Louise De Brot, Rodrigo G. Taboada, Mauro D. Donadio, Rachel P. Riechelmann
    Therapeutic Advances in Medical Oncology.2023;[Epub]     CrossRef
  • Diagnostic and Prognostic Impact of Progesterone Receptor Immunohistochemistry: A Study Evaluating More Than 16,000 Tumors
    Florian Viehweger, Lisa-Marie Tinger, David Dum, Natalia Gorbokon, Anne Menz, Ria Uhlig, Franziska Büscheck, Andreas M. Luebke, Claudia Hube-Magg, Andrea Hinsch, Doris Höflmayer, Christoph Fraune, Patrick Lebok, Sören Weidemann, Maximilian Lennartz, Frank
    Analytical Cellular Pathology.2022; 2022: 1.     CrossRef
  • Prognostic Nomograms to Predict Overall Survival and Cancer-Specific Survival of Patients With Pancreatic Neuroendocrine Tumors
    Zuoli Song, Sumei Wang, Yujing Wu, Jinjuan Zhang, Shuye Liu
    Pancreas.2021; 50(3): 414.     CrossRef
  • Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multicenter Study
    Haeryoung Kim, Soyeon An, Kyoungbun Lee, Sangjeong Ahn, Do Youn Park, Jo-Heon Kim, Dong-Wook Kang, Min-Ju Kim, Mee Soo Chang, Eun Sun Jung, Joon Mee Kim, Yoon Jung Choi, So-Young Jin, Hee Kyung Chang, Mee-Yon Cho, Yun Kyung Kang, Myunghee Kang, Soomin Ahn
    Cancer Research and Treatment.2020; 52(1): 263.     CrossRef
  • Systemic distribution of progesterone receptor subtypes in human tissues
    Teeranut Asavasupreechar, Ryoko Saito, Yasuhiro Miki, Dean P. Edwards, Viroj Boonyaratanakornkit, Hironobu Sasano
    The Journal of Steroid Biochemistry and Molecular Biology.2020; 199: 105599.     CrossRef
  • Progesteron receptor expression in insulin producing cells of neuroendocrine neoplasms
    Tomoyoshi Tachibana, Atsuko Kasajima, Takeshi Aoki, Tomoaki Tabata, Keely McNamara, Samaneh Yazdani, Sato Satoko, Fumiyoshi Fujishima, Fuyuhiko Motoi, Michiaki Unno, Hironobu Sasano
    The Journal of Steroid Biochemistry and Molecular Biology.2020; 201: 105694.     CrossRef
  • Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies
    Lingaku Lee, Tetsuhide Ito, Robert T Jensen
    Expert Review of Anticancer Therapy.2019; 19(12): 1029.     CrossRef
  • Immunohistochemistry, carcinomas of unknown primary, and incidence rates
    Edward B. Stelow, Hadi Yaziji
    Seminars in Diagnostic Pathology.2018; 35(2): 143.     CrossRef
  • Carbonic anhydrase 9 expression in well-differentiated pancreatic neuroendocrine neoplasms might be associated with aggressive behavior and poor survival
    Joo Young Kim, Sang Hwa Lee, Soyeon An, Sung Joo Kim, You-Na Sung, Ki-Byung Song, Dae Wook Hwang, Song Cheol Kim, Seung-Mo Hong
    Virchows Archiv.2018; 472(5): 739.     CrossRef
  • Prognostic value of progesterone receptor in solid pseudopapillary neoplasm of the pancreas: evaluation of a pooled case series
    Feiyang Wang, Zibo Meng, Shoukang Li, Yushun Zhang, Heshui Wu
    BMC Gastroenterology.2018;[Epub]     CrossRef
  • Estrogens modulate progesterone receptor expression and may contribute to progesterone-mediated apoptotic β-cell death
    Viviane Abreu Nunes
    Endocrinology&Metabolism International Journal.2018;[Epub]     CrossRef
Case Study
Mammary-Type Myofibroblastoma: A Report of Two Cases
Soyeon An, Joon Seon Song, Soonchan Park, Jung Won Lee, Kyung-Ja Cho
J Pathol Transl Med. 2016;50(5):385-389.   Published online June 6, 2016
DOI: https://doi.org/10.4132/jptm.2016.03.26
  • 9,554 View
  • 135 Download
  • 5 Web of Science
  • 8 Crossref
AbstractAbstract PDF
Mammary-type myofibroblastoma (MFB) is a rare, benign spindle cell neoplasm occurring along the milkline, with extension from the mid-axilla to the medial groin. It is histologically and immunohistochemically identical to MFB of the breast and is part of a spectrum of lesions that includes spindle cell lipoma and cellular angiofibroma. Recently, we experienced two cases of mammary-type MFB involving male patients aged 30 and 58 years, respectively. The tumors were located in the right scrotal sac and in the right axilla. Wide excisions were performed. Microscopically, the masses were composed of haphazardly arranged, variably sized fascicles of bland spindle cells and were admixed with mature fat tissue. The spindle cells in both cases showed immunopositivity for desmin and CD34 and negativity for smooth muscle actin. Loss of retinoblastoma (RB)/13q14 loci is a characteristic genetic alteration of mammary-type MFB, and we identified loss of RB protein expression by immunohistochemical staining. We emphasize the importance of awareness of this rare neoplasm when a spindle cell neoplasm is accompanied by desmin immunopositivity. The second patient was alive without recurrence for 20 months, and the first patient had not been followed.

Citations

Citations to this article as recorded by  
  • Myofibroblastoma in the Liver: A Case Report and Review of Literature
    Mohan Narasimhamurthy, Deepika Savant, Lauren Shreve, Mark A. Rosen, Major Kenneth Lee, Kumarasen Cooper, Emma E. Furth, Paul J. Zhang, Zhaohai Yang
    International Journal of Surgical Pathology.2023; 31(8): 1559.     CrossRef
  • Mammary-type myofibroblastoma of the thigh mimicking liposarcoma
    Natasha Akhlaq, Bibianna Purgina, Joel Werier, Zaid Jibri
    Skeletal Radiology.2022; 51(2): 441.     CrossRef
  • Mammary‐type myofibroblastoma of the perineum: Typical or rare location?
    Akihiro Naito, Yuta Takeshima, Sayuri Takahashi
    IJU Case Reports.2022; 5(3): 161.     CrossRef
  • Identifying the uncommon solitary fibrous tumour in a rare location – A case report
    Shanthi Periasamy, Anita Mani, Graham J. Stewart, Jacob P. Hampton
    International Journal of Surgery Case Reports.2022; 94: 107058.     CrossRef
  • Mammary-Type Myofibroblastoma of Perineal Region: A Case Report and Literature Review
    晓虹 江
    Advances in Clinical Medicine.2021; 11(04): 1722.     CrossRef
  • A case of mammary-type myofibroblastoma of the inguinal region
    Atsushi Ishihara, Takeo Yasuda, Yukari Sakae, Masayuki Sakae, Tooru Hamada, Hideki Tsukazaki, Takashi Tsukazaki, Masaru Furumoto
    International Journal of Surgery Case Reports.2018; 53: 464.     CrossRef
  • Radiologic presentation of a myofibroblastoma of the adult male breast
    Evan Rochlis, Pauline Germaine
    Radiology Case Reports.2017; 12(3): 439.     CrossRef
  • Imaging features of mammary-type myofibroblastoma of soft tissue: a case series with literature review
    Gokhan Kuyumcu, Brian P. Rubin, Carl Winalski
    Skeletal Radiology.2017; 46(9): 1283.     CrossRef
Original Article
Clinical and Prognostic Significances of Cytokeratin 19 and KIT Expression in Surgically Resectable Pancreatic Neuroendocrine Tumors
Eun-Mi Son, Joo Young Kim, Soyeon An, Ki-Byung Song, Song Cheol Kim, Eunsil Yu, Seung-Mo Hong
J Pathol Transl Med. 2015;49(1):30-36.   Published online January 15, 2015
DOI: https://doi.org/10.4132/jptm.2014.10.23
  • 10,388 View
  • 83 Download
  • 18 Web of Science
  • 17 Crossref
AbstractAbstract PDF
Background
Pancreatic neuroendocrine tumors (PanNETs) are malignant endocrine neoplasms that present diverse clinical behaviors. Therefore, identification of biomarkers of PanNETs is important for stratification of the prognosis of PanNET patients. Recently, cytokeratin 19 (CK19) and KIT expression were reported to have prognostic significance in PanNET patients. Methods: To identify their prognostic significance, CK19 and KIT protein expression were assessed in 182 surgically resected PanNETs and compared with clinicopathologic factors. Results: Of 182 PanNETs cases, CK19 and KIT expression was noted in 97 (53.3%) and 16 (8.8%) cases, respectively. PanNET patients with CK19 expression had larger tumors (p=.006), higher World Health Organization (WHO) grade (p=.002) and pT classification (p<.001), increased distant metastasis (p=.004), and lymphovascular (p=.012) and perineural (p=.019) invasion. Similarly, those with KIT expression had larger tumors (p=.030), higher WHO grade (p=.001), advanced pT classification (p<.001), distant metastasis (p=.001), and lymphovascular invasion (p=.014). The 5-year survival rate for PanNET patients with KIT expression was significantly lower (62%) than that of patients without KIT expression (77%, p=.011), as determined by univariate but not by multivariate analyses. Conclusions: CK19 and KIT expression correlate with higher metastatic potential and advanced disease stage, and KIT expression is associated with worse survival in PanNET patients.

Citations

Citations to this article as recorded by  
  • Combined Infiltrative Macroscopic Growth Pattern and Infiltrative Microscopic Tumor Border Status Is a Novel Surrogate Marker of Poor Prognosis in Patients With Pancreatic Neuroendocrine Tumor
    Bokyung Ahn, Joo Young Kim, Seung-Mo Hong
    Archives of Pathology & Laboratory Medicine.2023; 147(1): 100.     CrossRef
  • Tumor-associated nonmyelinating Schwann cell–expressed PVT1 promotes pancreatic cancer kynurenine pathway and tumor immune exclusion
    Chengcao Sun, Youqiong Ye, Zhi Tan, Yuan Liu, Yajuan Li, Wei Hu, Ke Liang, Sergey D. Egranov, Lisa Angela Huang, Zhao Zhang, Yaohua Zhang, Jun Yao, Tina K. Nguyen, Zilong Zhao, Andrew Wu, Jeffrey R. Marks, Abigail S. Caudle, Aysegul A. Sahin, Jianjun Gao,
    Science Advances.2023;[Epub]     CrossRef
  • Diagnostic and prognostic impact of cytokeratin 19 expression analysis in human tumors: a tissue microarray study of 13,172 tumors
    Anne Menz, Rifka Bauer, Martina Kluth, Clara Marie von Bargen, Natalia Gorbokon, Florian Viehweger, Maximilian Lennartz, Cosima Völkl, Christoph Fraune, Ria Uhlig, Claudia Hube-Magg, Noémi De Wispelaere, Sarah Minner, Guido Sauter, Simon Kind, Ronald Simo
    Human Pathology.2021; 115: 19.     CrossRef
  • The molecular biology of pancreatic neuroendocrine neoplasms: Challenges and translational opportunities
    Kate Young, Naureen Starling, Anguraj Sadanandam
    Seminars in Cancer Biology.2020; 61: 132.     CrossRef
  • Pancreatic acinar cell carcinomas and mixed acinar-neuroendocrine carcinomas are more clinically aggressive than grade 1 pancreatic neuroendocrine tumours
    Joo Young Kim, Jacqueline A. Brosnan-Cashman, Jiyoon Kim, Soyeon An, Kyoung-Bun Lee, Haeryoung Kim, Do Youn Park, Kee-Taek Jang, Young-Ha Oh, Ralph H. Hruban, Christopher M. Heaphy, Seung-Mo Hong
    Pathology.2020; 52(3): 336.     CrossRef
  • Morphologic Variants of Pancreatic Neuroendocrine Tumors: Clinicopathologic Analysis and Prognostic Stratification
    Yue Xue, Michelle D. Reid, Burcin Pehlivanoglu, Rebecca C. Obeng, Hongmei Jiang, Bahar Memis, Shu K. Lui, Juan Sarmiento, David Kooby, Shishir K. Maithel, Bassel El-Rayes, Olca Basturk, Volkan Adsay
    Endocrine Pathology.2020; 31(3): 239.     CrossRef
  • Histological grades and prognostic markers of well-differentiated pancreatic neuroendocrine tumor (WDPNET)
    Yongchao Li, Daniel Rowan, Claire P. Williamson, Meiyun Fan, Ali G. Saad, Lizhi Zhang
    Journal of Pancreatology.2020; 3(4): 188.     CrossRef
  • Clinical and histopathologic prognostic implications of the expression of cytokeratins 8, 10, 13, 14, 16, 18 and 19 in oral and oropharyngeal squamous cell carcinoma
    Rima A. Safadi, Niveen I. Abdullah, Rolla F. Alaaraj, Dima H. Bader, Darshan D. Divakar, Abed A. Hamasha, Maher A. Sughayer
    Archives of Oral Biology.2019; 99: 1.     CrossRef
  • Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies
    Lingaku Lee, Tetsuhide Ito, Robert T Jensen
    Expert Review of Anticancer Therapy.2019; 19(12): 1029.     CrossRef
  • Carbonic anhydrase 9 expression in well-differentiated pancreatic neuroendocrine neoplasms might be associated with aggressive behavior and poor survival
    Joo Young Kim, Sang Hwa Lee, Soyeon An, Sung Joo Kim, You-Na Sung, Ki-Byung Song, Dae Wook Hwang, Song Cheol Kim, Seung-Mo Hong
    Virchows Archiv.2018; 472(5): 739.     CrossRef
  • CD133 expression in well-differentiated pancreatic neuroendocrine tumors: a potential predictor of progressive clinical courses
    Yasuhiro Sakai, Seung-Mo Hong, Soyeon An, Joo Young Kim, Denis Corbeil, Jana Karbanová, Kyoko Otani, Kohei Fujikura, Ki-Byung Song, Song Cheol Kim, Masayuki Akita, Yoshihide Nanno, Hirochika Toyama, Takumi Fukumoto, Yonson Ku, Takanori Hirose, Tomoo Itoh,
    Human Pathology.2017; 61: 148.     CrossRef
  • Prognostic and predictive biomarkers in neuroendocrine tumours
    David L. Chan, Stephen J. Clarke, Connie I. Diakos, Paul J. Roach, Dale L. Bailey, Simron Singh, Nick Pavlakis
    Critical Reviews in Oncology/Hematology.2017; 113: 268.     CrossRef
  • Loss of Progesterone Receptor Expression Is an Early Tumorigenesis Event Associated with Tumor Progression and Shorter Survival in Pancreatic Neuroendocrine Tumor Patients
    Sung Joo Kim, Soyeon An, Jae Hoon Lee, Joo Young Kim, Ki-Byung Song, Dae Wook Hwang, Song Cheol Kim, Eunsil Yu, Seung-Mo Hong
    Journal of Pathology and Translational Medicine.2017; 51(4): 388.     CrossRef
  • Prognostic significance of cytokeratin 19 expression in pancreatic neuroendocrine tumor: A meta-analysis
    Dong Cen, Jiang Chen, Zheyong Li, Jie Zhao, Xiujun Cai, Aamir Ahmad
    PLOS ONE.2017; 12(11): e0187588.     CrossRef
  • A retrospective cohort study of pancreatic neuroendocrine tumors at single institution over 15 years: New proposal for low- and high-grade groups, validation of a nomogram for prognosis, and novel follow-up strategy for liver metastases
    Liangtao Ye, Huilin Ye, Quanbo Zhou, Zhihua Li, Qing Lin, Langping Tan, Wenchao Gao, Zhiqiang Fu, Shangyou Zheng, Rufu Chen
    International Journal of Surgery.2016; 29: 108.     CrossRef
  • Correlating and Combining Genomic and Proteomic Assessment withIn VivoMolecular Functional Imaging: Will This Be the Future Roadmap for Personalized Cancer Management?
    Bhakti Basu, Sandip Basu
    Cancer Biotherapy and Radiopharmaceuticals.2016; 31(3): 75.     CrossRef
  • Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts
    Joo Young Kim, Seung-Mo Hong
    Archives of Pathology & Laboratory Medicine.2016; 140(5): 437.     CrossRef

J Pathol Transl Med : Journal of Pathology and Translational Medicine